
|Articles|November 12, 2020
Pipeline: New therapies to come for debilitating eye diseases
New drug from Gensight Biologics hits pipeline
Advertisement
GenSight Biologics has developed a therapy for Leber hereditary optic neuropathy (LHON), called Lumevoq. The drug has been submitted for approval in Europe, and the company plans to submit for U.S. Food & Drug Administration approval in late 2021.
Dr. Gilly explains the mechanism of action for Lumevoq and provides a look into the GenSight Biologics pipeline for the future.
Newsletter
Want more insights like this? Subscribe to Optometry Times and get clinical pearls and practice tips delivered straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Optometry Times - Clinical News & Expert Optometrist Insights
1
What patients should know about contact lens technology with Dr Brieann Adair
2
Regeneron's Eylea HD injection 8 mg approved by FDA for the treatment of macular edema following RVO
3
2026 Medicare physician fee schedule shows increase for doctors of optometry
4
VSP Vision and the American Optometric Association collaborate on doctor contracting commitment
5


















































.png)


